Kevzara

Active Ingredient(s): Sarilumab
FDA Approved: * May 22, 2017
Pharm Company: * SANOFI SYNTHELABO
Category: Arthritis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kevzara Overview

Sarilumab (Kevzara) is a human monoclonal antibody against the interleukin-6 receptor.[1] Regeneron and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received FDA approval on May 22, 2017. Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[2] Contents 1 Clinical trials 1.1 Rheumatoid arthritis 2 History 3 Side effects of subcutaneous sarilumab 4 See al...

Read more Kevzara Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sarilumab

Recent Kevzara Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sarilumab
  • Injection: 150mg/1.14ml, 200mg/1.14ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kevzara: (2 results)

Sorted by National Drug Code
  • 0024-5908 Kevzara 150 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC
  • 0024-5910 Kevzara 200 mg/1.14ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC

Other drugs which contain Sarilumab or a similar ingredient: (1 result)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 22 September 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.